Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30466615 | 1.00 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL4678540 | 1.00 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL416894 | 0.98 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL996039 | 0.98 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL6259101 | 0.98 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Ammonia Solution, Strong SCHEMBL7204814 | 0.95 | TDP1 (0.39) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL28364770 | 0.88 | KIF11 (0.33) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL9538568 | 0.82 | TSHR (0.40) | KMT2ASMN1; SMN2KIF11SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1802201 | 0.82 | TSHR (0.40) | KMT2ASMN1; SMN2KIF11SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22164454 | 0.82 | ALDH1A1 (0.36) | KMT2ASMN1; SMN2KIF11SLC1A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| CN-109678740-A | A method of synthesis L- asparagine | 江苏鑫露化工新材料有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-108997155-A | A kind of polypeptide raw material aspartic acid β-tert-butyl ester α-methyl ester hydrochloride preparation method | 吉尔生化（上海）有限公司 | 2018-12-14 | — | — | CN | claimed |
| CN-103992337-B | A kind of method preparing Aspoxicillin sodium easily | 南京优科生物医药研究有限公司 | 2016-08-17 | — | — | CN | claimed |
| CN-101519490-A | Water-solubility polymer containing amino-acid or peptide radicals as well as preparation method and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2009-09-02 | — | — | CN | claimed |
| CN-1810795-A | Benzopyran compound and its prepn and use | SHANGHAI INST OF MEDICAMENTS C (CN) | 2006-08-02 | — | — | CN | claimed |
| CN-119638586-A | Trifluoromethyl cyclohexyl benzyl ether substituted nitrogenous organic acid derivative, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-03-18 | — | — | CN | disclosed |
| CN-115634224-B | Application of TERPESTACIN derivative in preparation of medicine for treating brain glioma | 中国科学院南海海洋研究所 | 2024-10-01 | — | — | CN | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-12011482-B2 | Chlorin derivatives or pharmaceutically acceptable salts thereof, preparation method and use thereof, and combination thereof with an ultrasonic medical system | GUANGZHOU EEC BIOTECH DEVELOPMENT CO., LTD. (CN) | 2024-06-18 | — | — | US | disclosed |
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-114751863-B | Terpastacin derivative, preparation method thereof and application thereof in preparation of hypoxia factor inhibitor | 中国科学院南海海洋研究所 | 2024-01-05 | — | — | CN | disclosed |
| EP-1202976-A1 | PYRAZINONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS | Merck Frosst Canada & Co. (CA) | 2002-05-08 | — | — | EP | disclosed |
| EP-1080067-A1 | BIODEGRADABLE CORROSION INHIBITORS | THE ASSOCIATED OCTEL COMPANY LIMITED (GB) | 2001-03-07 | — | — | EP | disclosed |
| WO-2001005772-A1 | PYRAZINONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS | MERCK FROSST CANADA & CO. (CA) | 2001-01-25 | — | — | WO | disclosed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999059958-A1 | BIODEGRADABLE CORROSION INHIBITORS | THE ASSOCIATED OCTEL COMPANY LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5326908-A | Process for the preparation of asparagine | NSC TECHNOLOGIES LLC | 1994-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011482-B2 | Chlorin derivatives or pharmaceutically acceptable salts thereof, preparation method and use thereof, and combination thereof with an ultrasonic medical system | STAT6, JAK3, JAK1 | S1PR1 3415/4885S1PR3 2791/4885KMT2A 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.